<SEC-DOCUMENT>0001193125-23-300042.txt : 20231220
<SEC-HEADER>0001193125-23-300042.hdr.sgml : 20231220
<ACCEPTANCE-DATETIME>20231220172259
ACCESSION NUMBER:		0001193125-23-300042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231220
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231220
DATE AS OF CHANGE:		20231220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		231502194

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d488420d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bmrn="http://www.bmrn.com/20231220" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-12-20_to_2023-12-20">BIOMARIN PHARMACEUTICAL INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-12-20_to_2023-12-20">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-12-20_to_2023-12-20">0001048477</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="bmrn-20231220.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-12-20_to_2023-12-20"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-20</xbrli:startDate> <xbrli:endDate>2023-12-20</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-12-20_to_2023-12-20">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt:datemonthdayyearen">December&#160;20, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">BioMarin Pharmaceutical Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-12-20_to_2023-12-20">000-26727</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-12-20_to_2023-12-20">68-0397820</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-12-20_to_2023-12-20">770 Lindaro Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-12-20_to_2023-12-20">San Rafael</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-12-20_to_2023-12-20">94901</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-12-20_to_2023-12-20">(415)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-12-20_to_2023-12-20">506-6700</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title&#160;of&#160;each&#160;class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name&#160;of&#160;each&#160;exchange<br />on&#160;which&#160;registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-12-20_to_2023-12-20">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-12-20_to_2023-12-20">BMRN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 20, 2023, BioMarin Pharmaceutical Inc. (the &#8220;Company&#8221;) announced that it had entered into a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P. (collectively, &#8220;Elliott&#8221;) regarding the composition of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), the establishment of an <span style="font-style:italic">ad hoc</span> Strategic and Operating Review Committee of the Board (the &#8220;Committee&#8221;) and certain other matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Cooperation Agreement, the Company has agreed, among other things, to (i)&#160;increase the size of the Board to 15 directors, (ii)&#160;appoint Barbara Bodem, Athena Countouriotis, M.D. and Mark Enyedy (the &#8220;New Directors&#8221;) as independent directors with initial terms expiring at the Company&#8217;s 2024 annual meeting of stockholders (the &#8220;2024 Annual Meeting&#8221;), (iii)&#160;nominate the New Directors for election as directors at the 2024 Annual Meeting, (iv)&#160;establish the Committee, (v)&#160;appoint Alexander Hardy, Richard Meier, Maykin Ho, Ph.D., Ms. Bodem and Mr. Enyedy to the Committee with Richard A. Meier as the Chair of the Committee and (vi)&#160;at an appropriate time following the Board reaching its determinations regarding the Committee&#8217;s review, hold an investor day in 2024 (&#8220;Investor Day&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee was established to conduct a review of the Company to maximize its long-term value, including a review of the business, strategy and operations of the Company, financial and capital allocation priorities and long-term planning and priorities. The Committee will make recommendations to the Board and will continue in existence until the later of the Investor Day and the date of the Company&#8217;s quarterly earnings announcement for the third quarter ended September&#160;30, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Cooperation Agreement, the size of the Board will be no greater than (i) 15 directors until the commencement of the 2024 Annual Meeting and (ii) 11 directors from the closing of the 2024 Annual Meeting until the termination or expiration of the Cooperation Period, which means the period from December 20,&#160;2023 until the earlier of (i)&#160;the date that is 30 calendar days prior to the notice deadline under the Company&#8217;s bylaws for the nomination of <span style="white-space:nowrap">non-proxy</span> access director candidates for election to the Board at the 2025 annual meeting of stockholders (the &#8220;2025 Annual Meeting&#8221;) and (ii)&#160;December&#160;20, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cooperation Agreement further provides that in the event that any New Director is unable or unwilling to serve, or resigns, is removed as a director or ceases to be a director of the Company for any other reason prior to the 2025 Annual Meeting, the Company and Elliott will cooperate in good faith to select, and the Company will appoint, a mutually agreeable replacement director to serve as a director of the Company for the remainder of the applicable New Director&#8217;s term, provided that at such time Elliott beneficially owns a &#8220;net long position&#8221; of, or has aggregate net long economic exposure to, at least 1.0% of the Company&#8217;s then outstanding shares of common stock, $0.001 par value (&#8220;Common Stock&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Cooperation Agreement, during the Cooperation Period, Elliott will abide by certain voting commitments and customary standstill restrictions (subject to certain exceptions), and the parties agree to mutual <span style="white-space:nowrap">non-disparagement</span> provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Cooperation Agreement, the Company and Elliott entered into an Information Sharing Agreement pertaining to the sharing of certain confidential information by the Company with Elliott in anticipation of (i)&#160;the Company&#8217;s presentation at the J.P. Morgan Healthcare Conference to be held January <span style="white-space:nowrap">8-11,</span> 2024, (ii) the Investor Day and (iii)&#160;subject to mutual agreement of the Company and Elliott, any Company quarterly or annual earnings announcement through the Company&#8217;s earnings announcement for the third quarter ended September&#160;30, 2024. The Information Sharing Agreement will terminate by its terms following the later to occur of the date of the Investor Day and the quarterly earnings announcement for the third quarter ended September&#160;30, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Cooperation Agreement is a summary, does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Cooperation Agreement, a copy of which is attached hereto and filed as Exhibit 10.1 and incorporated by reference herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;20, 2023, the size of the Board was expanded from 12 to 15 members in order to allow for the Board to appoint each of Ms.&#160;Bodem, Dr.&#160;Countouriotis and Mr.&#160;Enyedy to serve as a member of the Board, effective on December&#160;27, 2023. The Board also appointed each of Ms.&#160;Bodem and Mr.&#160;Enyedy as a member of the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee, in each case effective upon their appointment to the Board. The Board has not determined at this time which, if any, other committees Ms.&#160;Bodem, Dr.&#160;Countouriotis and Mr.&#160;Enyedy will be appointed to serve as a member. In connection with the appointments, the Board determined each of Ms.&#160;Bodem, Dr.&#160;Countouriotis and Mr.&#160;Enyedy to be independent directors within the meaning of the Nasdaq Stock Market listing standards and the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Barbara Bodem</span> has extensive Board experience, currently serving on a number of boards including Syneos Health, Enovis Corporation, and BiomEdit. Ms.&#160;Bodem is also a board member for the Nature Conservancy of Indiana, a nonprofit working to protect ecologically important lands and waters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&#160;Bodem recently served as Interim Chief Financial Officer for Dentsply Sirona Inc., the world&#8217;s largest manufacturer of professional dental products and technologies. This follows her time as Senior Vice President&#160;&amp; Chief Financial Officer, and interim CIO, for Hillrom where she was responsible for both financial and information technology and where she oversaw portfolio transformation and performance acceleration, which led to Hillrom&#8217;s successful acquisition by Baxter for $12&#160;billion, inclusive of debt. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this, Ms.&#160;Bodem was Senior Vice President of Finance for Mallinckrodt Pharmaceuticals. At Mallinckrodt, Ms.&#160;Bodem was responsible for corporate business development and licensing and reported to the Chief Financial Officer. Before this, she was Vice President of Finance, global commercial operations for Hospira and earlier held several positions of increasing responsibility at Eli Lilly and Company, culminating in Chief Financial Officer, Lilly Oncology. She began her career as a Financial Analyst for Irwin Management Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previously, Ms.&#160;Bodem served on the boards of Turning Point Therapeutics and Invacare Corporation. Ms.&#160;Bodem earned a M.B.A and a B.S. in Finance both at Indiana University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Athena </span><span style="font-weight:bold">Countouriotis</span><span style="font-weight:bold">, M.D.</span>, is co founder, President, Chief Executive Officer and Chairperson of Avenzo Therapeutics. She most recently led Turning Point Therapeutics as President and Chief Executive Officer through its initial public offering (IPO) to its eventual acquisition by Bristol Myers Squibb for $4.1&#160;billion in August 2022. With nearly 20 years of industry experience, she has served as an officer in both public and private companies, led multiple initial public offerings and acquisitions, and guided several development programs to approval in the U.S. and Europe. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Countouriotis previously served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, and as Senior Vice President and Chief Medical Officer of Halozyme Therapeutics. She also served as Chief Medical Officer of Ambit Biosciences, where she helped lead the company&#8217;s IPO and was responsible for the clinical development of Vanflyta<sup style="font-size:75%; vertical-align:top">&#174;</sup> until the company&#8217;s acquisition by Daiichi Sankyo in November 2014. Earlier in her career, Dr.&#160;Countouriotis led various clinical development organizations within Pfizer and Bristol Myers Squibb for oncology therapeutics including Sutent<sup style="font-size:75%; vertical-align:top">&#174;</sup>, Mylotarg<sup style="font-size:75%; vertical-align:top">&#8482;</sup>, Bosulif<sup style="font-size:75%; vertical-align:top">&#174;</sup> and Sprycel<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Countouriotis also serves on the boards of Iovance Biotherapeutics and Passage Bio. Dr.&#160;Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Mark Enyedy</span> has served as the President and Chief Executive Officer of ImmunoGen since 2016. Mr.&#160;Enyedy has nearly three decades of combined general management, business development and legal experience in the biotechnology industry. Mr.&#160;Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company&#8217;s strategy, M&amp;A, and corporate planning functions and providing commercial oversight for the company&#8217;s <span style="white-space:nowrap">pre-Phase</span> 3 portfolio. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previously, Mr.&#160;Enyedy served as Chief Executive Officer and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corporation in diverse roles, most recently as President of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr.&#160;Enyedy was an Associate with the Boston law firm Palmer&#160;&amp; Dodge. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Enyedy also serves on the boards of The American Cancer Society of Eastern New England and the Biotechnology Innovation Organization. He previously served on the boards of Ergomed plc, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals. Mr.&#160;Enyedy holds a J.D. from Harvard Law School and a B.S. from Northeastern University. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a <span style="white-space:nowrap">non-employee</span> director, each of the New Directors is entitled to receive the standard director fees paid to the Company&#8217;s <span style="white-space:nowrap">non-employee</span> directors and retainer fees paid to members of any Board committees on which he or she may sit, as described in the Company&#8217;s Definitive Proxy Statement on Schedule 14A (the &#8220;Proxy Statement), filed with the SEC on April&#160;11, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with his or her appointment to the Board, each of the New Directors will be granted a number of restricted stock units (the &#8220;RSU Grant&#8221;) valued at $200,000 pursuant to the Company&#8217;s 2017 Equity Incentive Plan, as amended, which is based on a pro rata share of the 2023 annual award for <span style="white-space:nowrap">non-employee</span> directors as described in the Proxy Statement and consistent with Company policy. The shares of Common Stock subject to the RSU Grant will vest on the date immediately prior to the date of the Company&#8217;s next regular annual meeting of stockholders, the same vesting date for the 2023 annual award for all other <span style="white-space:nowrap">non-employee</span> directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also intends to enter into indemnification agreements with each of the New Directors in the same form as the Company&#8217;s standard form indemnification agreement with its other directors, which is attached as Exhibit 10.2 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K,</span> filed with the SEC on December&#160;19, 2016. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than with respect to the matters referenced in Item 1.01 of this Current Report, none of Ms.&#160;Bodem, Dr.&#160;Countouriotis and Mr.&#160;Enyedy were selected by the Board to serve as a director pursuant to any arrangement or understanding with any person. None of Ms.&#160;Bodem, Dr.&#160;Countouriotis and Mr.&#160;Enyedy have engaged in any transaction that would be reportable as a related party transaction under Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth in Item 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated into this Item 5.02 by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 20, 2023, the Company issued a news release announcing the Company&#8217;s entry into the Cooperation Agreement and the matters described in Item 1.01 and Item 5.02 hereof. A copy of the news release is attached hereto and filed as Exhibit 99.1 and incorporated by reference herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d488420dex101.htm">Cooperation Agreement, dated as of December&#160;20, 2023, by and among the Company, Elliott Investment Management L.P., Elliott Associates, L.P. and Elliott International, L.P.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d488420dex991.htm">Press Release of the Company dated December 20, 2023.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMarin Pharmaceutical Inc.,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">a Delaware corporation</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: December&#160;20, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ G. Eric Davis</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">G. Eric Davis</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d488420dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COOPERATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Cooperation Agreement (this &#147;<U>Agreement</U>&#148;), dated as of December&nbsp;20, 2023 (the &#147;<U>Effective Date</U>&#148;), is
by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership and Elliott International, L.P., a Cayman Islands limited partnership (each, an &#147;<U>Elliott
Party</U>,&#148; and together, the &#147;<U>Elliott Parties</U>&#148;), and BioMarin Pharmaceutical Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;). Capitalized terms in this Agreement shall have the meanings set forth in this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Elliott Parties have engaged in certain discussions concerning the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Elliott Parties desire to enter into an agreement regarding the appointment of certain new independent directors
to the Board of Directors of the Company (the &#147;<U>Board</U>&#148;), the formation of a Strategic and Operating Review Committee of the Board (the &#147;<U>Committee</U>&#148;) and certain other matters, in each case, on the terms and subject to
the conditions set forth herein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, the Company and certain of the Elliott
Parties are entering into an information sharing agreement (the &#147;<U>Information Sharing Agreement</U>&#148;) to enable the Company to share certain confidential information, including in connection with the Company&#146;s anticipated
communications at the Investor Day (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of and reliance upon the mutual covenants and
agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Elliott Parties and the Company agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>New Directors; Strategic and Operating Review Committee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>New Director Appointments. </I>Within five business days following the Effective Date and subject to the satisfaction of the
Company&#146;s customary director onboarding procedures, the Board and all applicable committees thereof shall take (or shall have taken) such actions as are necessary to increase the size of the Board by three and appoint Mark Enyedy, Athena
Countouriotis and Barbara Bodem (the &#147;<U>New Directors</U>&#148;) as new members of the Board to fill the vacancies created by such increase in the size of the Board, with an initial term expiring at the Company&#146;s 2024 Annual Meeting of
Stockholders (the &#147;<U>2024 Annual Meeting</U>&#148;). The Company agrees that (i)&nbsp;from the Effective Date until the commencement of the 2024 Annual Meeting, the size of the Board shall be no greater than 15 directors and (ii)&nbsp;from the
closing of the 2024 Annual Meeting until the termination or expiration of the Cooperation Period (as defined below), the size of the Board shall be no greater than 11 directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Nomination of New Directors. </I>The Company agrees that, provided that a New Director is able and willing to serve on the Board and
continues to be a Qualified Director (as defined below): </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) at the 2024 Annual Meeting, the Board will nominate such New Director,
together with the other persons included in the Company&#146;s slate of nominees for election as a director at the 2024 Annual Meeting in accordance with this Section&nbsp;1(b), as a director of the Company, with a term expiring at the
Company&#146;s 2025 Annual Meeting of Stockholders (the &#147;<U>2025 Annual Meeting</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Board will
recommend that the stockholders of the Company vote to elect such New Director as a director of the Company at the 2024 Annual Meeting; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company will use its reasonable best efforts (which will include the solicitation of proxies) to obtain the election
of such New Director at the 2024 Annual Meeting (for the avoidance of doubt, the Company will only be required to use substantially the same level of efforts and provide substantially the same level of support as is used and/or provided for the
other director nominees of the Company with respect to the 2024 Annual Meeting). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>New Director Agreements, Arrangements and
Understandings. </I>Each of the Elliott Parties represents, warrants and agrees that neither it nor any of its Affiliates (as defined below)&nbsp;(i) has paid or will pay any compensation to any New Director in connection with such person&#146;s
service on the Board or any committee thereof, or (ii)&nbsp;has or will have any agreement, arrangement or understanding, written or oral, with any New Director in connection with such person&#146;s service on the Board or any committee thereof.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Replacement New Directors</I>. If any New Director is unable or unwilling to serve as a director, resigns as a director, is removed
as a director or ceases to be a director for any other reason prior to the 2025 Annual Meeting, and at such time the Elliott Parties satisfy the Minimum Ownership Threshold (as defined below), the Elliott Parties and the Company shall cooperate in
good faith to select, and the Company will appoint, as promptly as practicable, a Qualified Director mutually agreeable to the Company and the Elliott Parties (such person, the &#147;<U>Replacement New Director</U>&#148;), in each case, to serve as
a director of the Company for the remainder of the applicable New Director&#146;s term. Effective upon the appointment of the Replacement New Director to the Board, such Replacement New Director will be considered a New Director for all purposes of
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>New Director Information. </I>As a condition to a Replacement New Director&#146;s appointment to the Board and any
subsequent nomination of a New Director for election as a director at any future Company meeting of stockholders, such person will (i)&nbsp;provide any consents and information the Company reasonably requests in connection with such appointment or
nomination, including (A)&nbsp;the completion of the Company&#146;s standard forms, D&amp;O questionnaires and other customary onboarding or nomination documentation, (B)&nbsp;an executed consent to be named as a nominee in the Company&#146;s proxy
statement and to serve as a director if so elected for the full term for which such person is elected at any Company meeting of stockholders, in the case of clauses (A)&nbsp;and (B), in the form provided by the Company, (C)&nbsp;information required
to be disclosed in a proxy statement or other filing under applicable law, stock exchange rules or listing standards, (D)&nbsp;information requested or required by any regulatory or governmental authority having jurisdiction over the Company and its
Affiliates, and (E)&nbsp;information reasonably requested </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Company in connection with assessing eligibility, independence and other criteria applicable to directors or satisfying compliance and legal obligations, and (ii)&nbsp;consent to
appropriate background checks, in each case, to the extent the information and requests in clauses (i)&nbsp;and (ii) are consistent with the information or background checks, as applicable, required by the Company in accordance with past practice
with respect to other <FONT STYLE="white-space:nowrap">non-management</FONT> directors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Strategic and Operating
Review Committee</I>. As soon as reasonably practicable following the appointment of the New Directors, the Board shall take all action necessary to form the Committee to support the Board and management&#146;s reviews of the matters set forth in
the Committee&#146;s charter, and having such authority and responsibilities as set forth in the Committee&#146;s charter. The Board shall cause the Committee to be composed of five members, which shall initially consist of Richard Meier, Alexander
Hardy, Maykin Ho, Mark Enyedy and Barbara Bodem. Richard Meier shall be the initial Chair of the Committee. The initial charter of the Committee shall be in the form attached to this Agreement as <U>Exhibit B</U> (the &#147;<U>Committee
Charter</U>&#148;), and shall not be modified prior to the Investor Day except with the written consent of the Elliott Parties (such consent not to be unreasonably withheld, conditioned or delayed). The Company agrees that the Committee shall
continue in existence until the later of (i)&nbsp;the Investor Day and (ii)&nbsp;the Company&#146;s quarterly earnings announcement for the third quarter ended September&nbsp;30, 2024. If any New Director who is a member of the Committee is unable
or unwilling to serve as a member of the Committee, resigns as a member, is removed as a member or ceases to be a member for any reason, and at such time the Elliott Parties satisfy the Minimum Ownership Threshold, the Elliott Parties and the
Company shall cooperate in good faith to select, and the Board will appoint, as promptly as practicable, an Independent director serving on the Board at the time of such selection (including a Replacement New Director appointed pursuant to
Section&nbsp;1(d)) mutually agreeable to the Company and the Elliott Parties to serve on the Committee as a replacement for such member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Investor Day</I>. Following the delivery of the results of the Committee&#146;s review as contemplated by the Committee Charter, the
Company shall hold an investor day at an appropriate time following the Board reaching its determinations regarding the Committee&#146;s review, prior to September&nbsp;30, 2024 or such other date prior to December&nbsp;31, 2024 as the Board
reasonably determines is necessary, on the advice of counsel and acting in good faith, to prevent disclosure of any information or event at such investor day that would reasonably be expected to require disclosure under the federal securities laws
(the&nbsp;&#147;<U>Investor Day</U>&#148;), consistent with the Press Release (as defined below) and as contemplated by the Committee Charter. Subject to the foregoing sentence, the date of the Investor Day shall be determined by the Board and
management of the Company, and the Board and management of the Company shall have the discretion to determine to execute on or announce any initiatives or announce the completion of any initiatives prior to the Investor Day, in each case in
consultation with the Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Company Policies. </I>The parties acknowledge that each of the New Directors, upon election or
appointment to the Board, will be governed by the same protections and obligations regarding confidentiality, conflicts of interest, related party transactions, fiduciary duties, codes of conduct, trading and disclosure policies, director
resignation policy, and other governance guidelines and policies of the Company as other directors of the Company (collectively, &#147;<U>Company Policies</U>&#148;), and shall have the same rights and benefits, including with respect to insurance,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indemnification, compensation and fees, as are applicable to all independent directors of the Company. The Company agrees and acknowledges that no Company Policy currently does, and no Company
Policy at any time during the Cooperation Period will, prohibit any member of the Board (including any New Director) from communicating with the Elliott Parties or their Representatives (as defined below), subject to such director&#146;s observance
of standard confidentiality obligations and fiduciary duties to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Termination.</I> The Company&#146;s obligations under
this Section&nbsp;1 shall terminate upon any material breach of this Agreement (including Section&nbsp;2) by any Elliott Party upon five business days&#146; written notice by the Company to the Elliott Parties if such breach has not been cured
within such notice period, provided that the Company is not in material breach of this Agreement at the time such notice is given or prior to the end of the notice period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Cooperation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I><FONT
STYLE="white-space:nowrap">Non-Disparagement.</FONT> </I>Each of the Elliott Parties and the Company agrees that, from the Effective Date until the earlier of (i)&nbsp;the date that is 30 calendar days prior to the notice deadline under the
Company&#146;s Bylaws for the nomination of <FONT STYLE="white-space:nowrap">non-proxy</FONT> access director candidates for election to the Board at the 2025 Annual Meeting and (ii)&nbsp;December&nbsp;20, 2024 (such period, the &#147;<U>Cooperation
Period</U>&#148;), the Company and each Elliott Party shall refrain from making, and shall cause their respective controlling and controlled (and under common control) Affiliates and its and their respective principals, directors, members, general
partners, officers and employees (collectively, &#147;<U>Covered Persons</U>&#148;) not to make or cause to be made, any statement or announcement that constitutes an ad hominem attack on, or that otherwise disparages, defames, slanders, impugns or
is reasonably likely to damage the reputation of (A)&nbsp;in the case of any such statements or announcements by any of the Elliott Parties or their Covered Persons, the Company and its Affiliates or any of its or their current or former Covered
Persons and (B)&nbsp;in the case of any such statements or announcements by the Company or its Covered Persons, the Elliott Parties and their Affiliates or any of their current or former Covered Persons, in each case including (x)&nbsp;in any
statement (oral or written), document or report filed with, furnished or otherwise provided to the SEC (as defined below) or any other governmental agency or regulatory authority, (y)&nbsp;in any press release or other publicly available format, or
(z)&nbsp;to any journalist or member of the media (including, in a television, radio, newspaper, podcast or magazine interview or Internet or social media communication). The foregoing shall not (1)&nbsp;restrict the ability of any person to comply
with any subpoena or other legal process or respond to a request for information from any governmental or regulatory authority with jurisdiction over the party from whom information is sought or to enforce such person&#146;s rights hereunder or
(2)&nbsp;apply to any private communications among the Elliott Parties and their Affiliates, Covered Persons and Representatives (in their capacity as such), on the one hand, and among the Company and its Affiliates, Covered Persons and
Representatives (in their capacity as such), on the other hand. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Voting of the Elliott Parties&#146; Shares. </I>During the
Cooperation Period, each Elliott Party will cause all of the outstanding common shares, par value $0.001, of the Company (&#147;<U>Company Common Shares</U>&#148;) that such Elliott Party or any of its controlling or controlled (or under common
control) Affiliates has the right to vote (or to direct the vote) as of the applicable record date, to be present in person or by proxy for quorum purposes and to be voted at any meeting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of stockholders of the Company or at any adjournments or postponements thereof, and to consent, and deliver such consent in connection with any action by written consent in lieu of a meeting,
(i)&nbsp;in favor of each director nominated and recommended by the Board for election at the 2024 Annual Meeting, or, if applicable, any other meeting of stockholders of the Company or through any action by written consent of stockholders of the
Company, in each case, during the Cooperation Period, (ii)&nbsp;against any stockholder nominations for director that are not approved and recommended by the Board for election at any such meeting or through any such written consent,
(iii)&nbsp;against any proposals or resolutions to remove any member of the Board (unless such proposal or resolution is supported by the Board), and (iv)&nbsp;in accordance with recommendations by the Board on all other proposals or business that
may be the subject of stockholder action at such meetings or in such written consents; <U>provided</U>, however, that the Elliott Parties and their Affiliates shall be permitted to vote in their sole discretion on any proposals related to any
Extraordinary Transaction (as defined below); <U>provided</U>, further, that in the event that both Institutional Shareholder Services and Glass Lewis&nbsp;&amp; Co. (including any successors thereof) issue a voting recommendation that differs from
the voting recommendation of the Board with respect to any Company-sponsored proposal submitted to stockholders at a stockholder meeting (other than with respect to the election of directors to the Board, the removal of directors from the Board, the
size of the Board and the filling of vacancies on the Board), the Elliott Parties and their Affiliates shall be permitted to vote in accordance with any such recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Standstill. </I>During the Cooperation Period, each Elliott Party will not, and will cause its controlling and controlled (and under
common control) Affiliates and its and their respective Representatives acting on their behalf (collectively with the Elliott Parties, the &#147;<U>Restricted Persons</U>&#148;) to not, directly or indirectly, without the prior written consent,
invitation, or authorization of the Company or the Board: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) acquire, or offer or agree to acquire, by purchase or
otherwise, or direct any Third Party (as defined below) in the acquisition of record or beneficial ownership of or economic exposure to any Voting Securities (as defined below) or engage in any swap or hedging transactions or other derivative
agreements of any nature with respect to any Voting Securities, in each case, if such acquisition, offer, agreement or transaction would result in the Elliott Parties (together with their Affiliates) having beneficial ownership of, or aggregate
economic exposure to, more than 9.9% of the Company Common Shares outstanding at such time; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) (A) call or seek to call
(publicly or otherwise), alone or in concert with others, a meeting of the Company&#146;s stockholders or act by written consent in lieu of a meeting (or the setting of a record date therefor), (B) seek, alone or in concert with others, election or
appointment to, or representation on, the Board or nominate or propose the nomination of, or recommend the nomination of, any candidate to the Board, except as expressly set forth in Section&nbsp;1, (C) make or be the proponent of any stockholder
proposal to the Company or the Board or any committee thereof, (D)&nbsp;seek, alone or in concert with others (including through any &#147;withhold&#148; or similar campaign), the removal of any member of the Board, or (E)&nbsp;conduct a referendum
of stockholders of the Company; <U>provided</U> that nothing in this Agreement will prevent the Elliott Parties or their Affiliates from taking actions in furtherance of identifying any Replacement New Director in accordance with Section&nbsp;1(d),
as applicable; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) make any request for stock list materials or other books and records
of the Company or any of its subsidiaries under Section&nbsp;220 of the Delaware General Corporation Law or any other statutory or regulatory provisions providing for stockholder access to books and records; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) engage in any &#147;solicitation&#148; (as such term is used in the proxy rules promulgated under the Exchange Act (as
defined below)) of proxies or consents with respect to the election or removal of directors of the Company or any other matter or proposal relating to the Company or become a &#147;participant&#148; (as such term is defined in Instruction 3 to Item
4 of Schedule 14A promulgated under the Exchange Act) in any such solicitation of proxies or consents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) make or submit
to the Company or any of its Affiliates any proposal for, or offer of (with or without conditions), either alone or in concert with others, any tender offer, exchange offer, merger, consolidation, acquisition, business combination, sale of all or
substantially all assets, recapitalization, restructuring, liquidation, dissolution or similar extraordinary transaction involving the Company (including its subsidiaries and joint ventures or any of their respective securities or assets) (each, an
&#147;<U>Extraordinary Transaction</U>&#148;), either publicly or in a manner that would reasonably be expected to require public disclosure by the Company or any of the Restricted Persons (it being understood that the foregoing shall not restrict
the Restricted Persons from tendering shares, receiving consideration or other payment for shares, or otherwise participating in any Extraordinary Transaction on the same basis as other stockholders of the Company); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) make any public proposal with respect to (A)&nbsp;any change in the number or identity of directors of the Company or the
filling of any vacancies on the Board other than as provided under Section&nbsp;1 of this Agreement, (B)&nbsp;any change in the capitalization, capital allocation policy or dividend policy of the Company, (C)&nbsp;any other change to the Board or
the Company&#146;s management or corporate or governance structure, (D)&nbsp;any waiver, amendment or modification to the Company&#146;s Articles of Incorporation or the Bylaws, as amended, (E)&nbsp;causing the Company Common Shares to be delisted
from, or to cease to be authorized to be quoted on, any securities exchange or (F)&nbsp;causing the Company Common Shares to become eligible for termination of registration pursuant to Section&nbsp;12(g)(4) of the Exchange Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) knowingly encourage or advise any Third Party or knowingly assist any Third Party in encouraging or advising any other
person with respect to (A)&nbsp;the giving or withholding of any proxy relating to, or other authority to vote, any Voting Securities, or (B)&nbsp;conducting any type of referendum relating to the Company, other than such encouragement or advice
that is consistent with the Board&#146;s recommendation in connection with such matter, or as otherwise specifically permitted under this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) form, join or act in concert with any &#147;group&#148; as defined in
Section&nbsp;13(d)(3) of the Exchange Act, with respect to any Voting Securities, other than solely with Affiliates of the Elliott Parties with respect to Voting Securities now or hereafter owned by them; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) enter into a voting trust, arrangement or agreement with respect to any Voting Securities, or subject any Voting
Securities to any voting trust, arrangement or agreement (excluding customary brokerage accounts, margin accounts, prime brokerage accounts and the like), in each case other than (A)&nbsp;this Agreement (B)&nbsp;solely with Affiliates of the Elliott
Parties or (C)&nbsp;granting proxies in solicitations approved by the Board; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) engage in any short sale or any purchase,
sale, or grant of any option, warrant, convertible security, share appreciation right, or other similar right (including any put or call option or &#147;swap&#148; transaction) with respect to any security (other than any index fund, exchange traded
fund, benchmark fund or broad basket of securities) that includes, relates to, or derives any significant part of its value from a decline in the market price or value of the Voting Securities and would, in the aggregate or individually, result in
the Elliott Parties ceasing to have a &#147;net long position&#148; in the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) sell, offer or agree to sell, all
or substantially all, directly or indirectly, through swap or hedging transactions or otherwise, voting rights decoupled from the underlying Voting Securities held by a Restricted Person to any Third Party; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) institute, solicit or join as a party any litigation, arbitration or other proceeding against or involving the Company or
any of its subsidiaries or any of its or their respective current or former directors or officers (including derivative actions); provided, however, that for the avoidance of doubt, the foregoing shall not prevent any Restricted Person from
(A)&nbsp;bringing litigation against the Company to enforce any provision of this Agreement instituted in accordance with and subject to Section&nbsp;9, (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the
Company or its Affiliates against a Restricted Person, (C)&nbsp;bringing bona fide commercial disputes that do not relate to the subject matter of this Agreement, (D)&nbsp;exercising statutory appraisal rights or (E)&nbsp;responding to or complying
with a validly issued legal process; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) enter into any negotiations, agreements, arrangements, or understandings
(whether written or oral) with any Third Party to take any action that the Restricted Persons are prohibited from taking pursuant to this Section&nbsp;2(c); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) make any request or submit any proposal to amend or waive the terms of this Agreement (including this subclause) or the
Committee Charter, in each case publicly or which would reasonably be expected to result in a public announcement or disclosure of such request or proposal; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U> that the restrictions in this Section&nbsp;2(c) shall
terminate automatically upon the earliest of the following: (A)&nbsp;any material breach of this Agreement by the Company (including, without limitation, a failure to appoint the New Directors to the Board or the Committee in accordance with
Sections&nbsp;1(a) and 1(f), form the Committee in accordance with Section&nbsp;1(f), include the New Directors in the slate of nominees recommended by the Board in the Company&#146;s proxy statement and on its proxy card relating to the 2024 Annual
Meeting in accordance with Section&nbsp;1(b), or issue the Press Release in accordance with Section&nbsp;3) upon five business days&#146; written notice by any of the Elliott Parties to the Company if such breach has not been cured within such
notice period, provided that the Elliott Parties are not in material breach of this Agreement at the time such notice is given or prior to the end of the notice period; (B)&nbsp;the Company&#146;s entry into (x)&nbsp;a definitive agreement with
respect to any Extraordinary Transaction that would result in the acquisition by any person or group of more than 50% of the Voting Securities or assets having an aggregate value exceeding 50% of the aggregate enterprise value of the Company,
(y)&nbsp;one or more definitive agreements providing for the acquisition by the Company or its subsidiaries of one or more businesses or assets (excluding, for the avoidance of doubt, acquisitions of raw materials, equipment or facilities in
ordinary course business operations) having an aggregate value exceeding 25% of the market capitalization of the Company during the Cooperation Period or (z)&nbsp;one or more definitive agreements providing for a transaction or series of related
transactions which would in the aggregate result in the Company issuing to one or more Third Parties at least 10% of the Company Common Shares (including on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and including other Voting
Securities with comparable voting power) outstanding immediately prior to such issuance(s) (including in a PIPE, convertible note, convertible preferred security or similar structure) during the Cooperation Period (provided that securities issued as
consideration for (or in connection with) the acquisition of the assets, securities and/or business(es) of another person by the Company or one or more of its subsidiaries shall not be counted toward this clause (z)); and (C)&nbsp;the commencement
of any tender or exchange offer (by any person or group other than the Elliott Parties or their Affiliates) which, if consummated, would constitute an Extraordinary Transaction that would result in the acquisition by any person or group of more than
50% of the Voting Securities, where the Company files with the SEC a Schedule <FONT STYLE="white-space:nowrap">14D-9</FONT> (or amendment thereto) that does not recommend that its stockholders reject such tender or exchange offer (it being
understood that nothing herein will prevent the Company from issuing a &#147;stop, look and listen&#148; communication pursuant to Rule <FONT STYLE="white-space:nowrap">14d-9(f)</FONT> promulgated by the SEC under the Exchange Act in response to the
commencement of any tender or exchange offer). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement (including but not
limited to the restrictions in this Section&nbsp;2(c)) will prohibit or restrict any of the Restricted Persons from (I)&nbsp;making any public or private statement or announcement with respect to any Extraordinary Transaction that is publicly
announced by the Company or such Third Party, (II)&nbsp;making any factual statement to comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over such person from
whom information is sought (so long as such process or request did not arise as a result of discretionary acts by any Restricted Person), (III) granting any liens or encumbrances on any claims or interests in favor of a bank or broker-dealer or
prime broker holding such claims or interests in custody or prime brokerage in the ordinary course of business, which lien or encumbrance is released upon the transfer of such claims or interests in accordance with the terms of the custody or prime
brokerage agreement(s), as applicable, (IV)&nbsp;negotiating, evaluating and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trading, directly or indirectly, in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise reflect the performance of, but not primarily
consist of, securities of the Company or (V)&nbsp;privately communicating with the Board or the Company&#146;s senior executives, or members of the investor relations team made available for communications involving broad-based groups of investors
(including through participation in investor meetings and/or conferences), regarding any matter, or privately requesting a waiver of any provision of this Agreement, as long as such private communications or requests would not reasonably be expected
to require public disclosure of such communications or requests by the Company or any of the Restricted Persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Public
Announcement</U>. Not later than 4:30 p.m. Eastern Time on December&nbsp;20, 2023, the Company shall issue a press release in the form attached to this Agreement as <U>Exhibit A</U> (the &#147;<U>Press Release</U>&#148;). Substantially concurrently
with the issuance of the Press Release (and not later than 5:30 p.m. Eastern Time on December&nbsp;20, 2023), the Company shall file with the SEC a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<U>Form <FONT
STYLE="white-space:nowrap">8-K</FONT></U>&#148;) disclosing its entry into this Agreement and including a copy of this Agreement and the Press Release as exhibits thereto. The Company shall provide the Elliott Parties and their Representatives with
a copy of such Form <FONT STYLE="white-space:nowrap">8-K</FONT> prior to its filing with the SEC and shall consider any reasonable and timely comments of the Elliott Parties and their Representatives. Neither of the Company or any of its Affiliates
nor the Elliott Parties or any of their Affiliates shall make any public statement regarding the subject matter of this Agreement, this Agreement or the matters set forth in the Press Release prior to the issuance of the Press Release without the
prior written consent of the other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to
the Elliott Parties as follows: (a)&nbsp;the Company has the power and authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions contemplated by this Agreement; (b)&nbsp;this Agreement
has been duly and validly authorized, executed, and delivered by the Company, constitutes a valid and binding obligation and agreement of the Company and, assuming the valid execution and delivery hereof by each of the other parties hereto, is
enforceable against the Company in accordance with its terms, except as enforcement of this Agreement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or similar laws generally affecting the
rights of creditors and subject to general equity principles; and (c)&nbsp;the execution, delivery and performance of this Agreement by the Company does not and will not (i)&nbsp;violate or conflict with any law, rule, regulation, order, judgment or
decree applicable to the Company, or (ii)&nbsp;result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute a breach, violation or default) under or pursuant to, or result in
the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which the Company is a party or by
which it is bound. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Representations and Warranties of the Elliott Parties</U>. Each Elliott Party represents and warrants to the
Company as follows: (a)&nbsp;such Elliott Party has the power and authority to execute, deliver and carry out the terms and provisions of this Agreement and to consummate the transactions contemplated by this Agreement; (b)&nbsp;this Agreement has
been duly and validly authorized, executed, and delivered by such Elliott Party, constitutes a valid and binding obligation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and agreement of such Elliott Party and, assuming the valid execution and delivery hereof by each of the other parties hereto, is enforceable against such Elliott Party in accordance with its
terms, except as enforcement of this Agreement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or similar laws generally affecting the rights of creditors and subject to general equity
principles; and (c)&nbsp;the execution, delivery and performance of this Agreement by such Elliott Party does not and will not (i)&nbsp;violate or conflict with any law, rule, regulation, order, judgment or decree applicable to such Elliott Party,
or (ii)&nbsp;result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both could constitute a breach, violation or default) under or pursuant to, or result in the loss of a material benefit
under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such Elliott Party is a party or by which it is bound. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Definitions</U>. For purposes of this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the term &#147;<U>Affiliate</U>&#148; has the meaning set forth in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated by the
SEC under the Exchange Act and, for the avoidance of doubt, shall include persons who become Affiliates of any person on or subsequent to the date of this Agreement; <U>provided</U>, that none of the Company or its Affiliates or Representatives, on
the one hand, and the Elliott Parties and their Affiliates or Representatives, on the other hand, shall be deemed to be &#147;Affiliates&#148; with respect to the other for purposes of this Agreement; <U>provided</U>, further, that
&#147;Affiliates&#148; of a person shall not include any entity, solely by reason of the fact that one or more of such person&#146;s employees or principals serves as a member of its board of directors or similar governing body, unless such person
otherwise controls such entity (as the term &#147;control&#148; is defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated by the SEC under the Exchange Act); <U>provided</U>, further, that with respect to the Elliott Parties,
&#147;Affiliates&#148; shall not include any portfolio operating company (as such term is understood in the private equity industry) of any of the Elliott Parties or their Affiliates (unless such portfolio operating company is acting at the
direction of the Elliott Parties or any of their Affiliates to engage in conduct that is prohibited by this Agreement); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the terms
&#147;<U>beneficial owner</U>&#148; and &#147;<U>beneficially own</U>&#148; have the meaning set forth in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated by the SEC under the Exchange Act except that a person will also be deemed to be
the beneficial owner of all shares of the Company&#146;s capital stock which such person has the right to acquire (whether such right is exercisable immediately or only after the passage of time) pursuant to the exercise of any rights in connection
with any securities or any agreement, arrangement or understanding (whether or not in writing), regardless of when such rights may be exercised and whether they are conditional, and all shares of the Company&#146;s capital stock which such person or
any of such person&#146;s Affiliates has or shares the right to vote or dispose; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the term &#147;<U>business day</U>&#148; means any
day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New York is closed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the term &#147;<U>Exchange
Act</U>&#148; means the Securities Exchange Act of 1934; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the term &#147;<U>Independent</U>&#148; means that such person qualifies as independent
of the Company under all applicable listing standards, applicable rules of the SEC and publicly disclosed standards used by the Board in determining the independence of the Company&#146;s directors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the term &#147;<U>Minimum Ownership Threshold</U>&#148; means aggregate beneficial ownership of a &#147;net long position&#148; of, or
having aggregate net long exposure to, at least 1.0% of the then outstanding Company Common Shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the term &#147;<U>net long
position</U>&#148; has the meaning set forth in Rule <FONT STYLE="white-space:nowrap">14e-4</FONT> promulgated by the SEC under the Exchange Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) the terms &#147;<U>person</U>&#148; or &#147;<U>persons</U>&#148; shall be interpreted broadly to include any individual, corporation
(including <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit),</FONT></FONT> general or limited partnership, limited liability or unlimited liability company, joint venture, estate, trust, association, organization or
other entity of any kind or nature; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the term &#147;<U>Qualified Director</U>&#148; means an individual who (i)&nbsp;qualifies as
Independent, (ii)&nbsp;is not an employee, officer, director, general partner, manager or other agent of an Elliott Party or of any Affiliate of an Elliott Party, (iii)&nbsp;unless the Company otherwise consents, is not a limited partner, member or
other investor (unless such investment has been disclosed to the Company) in any Elliott Party or any Affiliate of an Elliott Party, (iv)&nbsp;does not have any agreement, arrangement or understanding, written or oral, with any Elliott Party or any
Affiliate of an Elliott Party regarding such person&#146;s service as a director on the Board, and (v)&nbsp;meets all other qualifications required for service as a director set forth in the Bylaws and the Company&#146;s Corporate Governance
Principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) the term &#147;<U>Representatives</U>&#148; means a party&#146;s directors, principals, members, general partners,
managers, officers, employees, agents, and other representatives; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) the term &#147;<U>SEC</U>&#148; means the U.S. Securities and
Exchange Commission; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) the term &#147;<U>Third Party</U>&#148; means any person that is not a party to this Agreement or an Affiliate
thereof, a director or officer of the Company, or legal counsel to any party to this Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) the term &#147;<U>Voting
Securities</U>&#148; means the Company Common Shares and any other Company securities entitled to vote in the election of directors, or securities convertible into, or exercisable or exchangeable for, such shares or other securities (including, for
the avoidance of doubt, convertible notes or other convertible debt securities), whether or not subject to the passage of time or other contingencies; provided that as pertains to any obligations of the Elliott Parties or any Restricted Persons
hereunder (including under Section&nbsp;2(c)), &#147;<U>Voting Securities</U>&#148; will not include any securities contained in any index fund, exchange traded fund, benchmark fund or broad basket of securities which may contain or otherwise
reflect the performance of, but not primarily consist of, securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Notices</U>. All notices, consents, requests, instructions, approvals and other
communications provided for herein and all legal process in regard to this Agreement will be in writing and will be deemed validly given, made, delivered or served, if (a)&nbsp;given by email, when sent to the email address set forth below (as
applicable), (b) given by a nationally recognized overnight carrier, one business day after being sent, or (c)&nbsp;if given by any other means, when actually received during normal business hours at the address specified in this Section: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">if&nbsp;to&nbsp;the&nbsp;Company:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">BioMarin Pharmaceutical Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">105 Digital Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Novato,
California 94949 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Eric Davis, Chief Legal Officer </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">edavis@bmrn.com </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">with&nbsp;a&nbsp;copy&nbsp;(which&nbsp;shall&nbsp;not</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">constitute notice) to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Jones Day </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">250 Vesey Street
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">New York City, NY 10281 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Andrew M. Levine </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amlevine@jonesday.com </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">and: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Jones Day </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">500 Grant Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Suite 4500
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Pittsburgh, PA 15219 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">David A. Grubman </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">dgrubman@jonesday.com </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="18%" VALIGN="top" ALIGN="left">if&nbsp;to&nbsp;the&nbsp;Elliott&nbsp;Parties:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Elliott Associates, L.P. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Elliott International, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">c/o Elliott Investment Management, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">360 S. Rosemary Ave., 18th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">West Palm Beach, Florida 33401 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Marc Steinberg </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Scott Grinsell </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mSteinberg@elliottmgmt.com </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sGrinsell@elliottmgmt.com </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">Olshan Frome Wolosky LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">1325
Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:22%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Steve Wolosky </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kenneth Mantel </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Email:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">swolosky@olshanlaw.com </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">kmantel@olshanlaw.com </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time, any party hereto may, by notice given in accordance with this Section&nbsp;7 to the other party, provide updated information for notices
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Expenses</U>. All fees, costs and expenses incurred in connection with this Agreement and all matters related to this
Agreement will be paid by the party incurring such fees, costs or expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Specific Performance; Remedies; Venue; Waiver of Jury
Trial</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company and the Elliott Parties acknowledge and agree that irreparable injury to the other party hereto would occur in
the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable by the remedies available at law (including the payment
of money damages). It is accordingly agreed that the Company and the Elliott Parties will be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to seek to enforce specifically the terms and provisions of this
Agreement, in addition to any other remedy to which they are entitled at law or in equity. FURTHERMORE, THE COMPANY AND EACH ELLIOTT PARTY AGREES (1)&nbsp;THE <FONT STYLE="white-space:nowrap">NON-BREACHING</FONT> PARTY WILL BE ENTITLED TO INJUNCTIVE
AND OTHER EQUITABLE RELIEF, WITHOUT PROOF OF ACTUAL DAMAGES, (2)&nbsp;THE BREACHING PARTY WILL NOT PLEAD IN DEFENSE THERETO THAT THERE WOULD BE AN ADEQUATE REMEDY AT LAW, AND (3)&nbsp;THE BREACHING PARTY AGREES TO WAIVE ANY BONDING REQUIREMENT UNDER
ANY APPLICABLE LAW, IN THE CASE THAT ANY OTHER PARTY SEEKS TO ENFORCE THE TERMS BY WAY OF EQUITABLE RELIEF. THIS AGREEMENT WILL BE GOVERNED IN ALL RESPECTS, INCLUDING VALIDITY, INTERPRETATION AND EFFECT, BY THE LAWS OF THE STATE OF DELAWARE WITHOUT
GIVING EFFECT TO THE CHOICE OF LAW PRINCIPLES OF SUCH STATE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company and each Elliott Party (a)&nbsp;irrevocably and
unconditionally submits to the exclusive jurisdiction of the Delaware Court of Chancery (or, only if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, the federal or other state courts located in Wilmington,
Delaware), (b) agrees that it will not attempt to deny or defeat such jurisdiction by motion or other request for leave from any such courts, (c)&nbsp;agrees that any actions or proceedings arising in connection with this Agreement or the
transactions contemplated by this Agreement shall be brought, tried and determined only in such courts, (d)&nbsp;waives any claim of improper venue or any claim that those courts are an inconvenient forum and (e)&nbsp;agrees that it will not bring
any action relating to this Agreement or the transactions contemplated hereunder in any court other than the aforesaid courts. The parties to this Agreement agree that mailing of process or other papers in connection with any such action or
proceeding in the manner provided in Section&nbsp;7 or in such other manner as may be permitted by applicable law as sufficient service of process, shall be valid and sufficient service thereof; <U>provided</U> that such process or other papers in
connection with any such action or proceeding is also contemporaneously delivered to the email address of such party set forth in Section&nbsp;7 hereof (for the avoidance of doubt, such email shall not in and of itself constitute effective service
of process). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each of the parties, after consulting or having had the opportunity to consult with
counsel, knowingly, voluntarily and intentionally waives any right that such party may have to a trial by jury in any litigation based upon or arising out of this Agreement or any related instrument or agreement, or any of the transactions
contemplated thereby, or any course of conduct, dealing, statements (whether oral or written), or actions of any of them. No party hereto shall seek to consolidate, by counterclaim or otherwise, any action in which a jury trial has been waived with
any other action in which a jury trial cannot be or has not been waived. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Severability</U>. If at any time subsequent to the
Effective Date, any provision of this Agreement is held by any court of competent jurisdiction to be illegal, void or unenforceable, such provision will be of no force and effect, but the illegality or unenforceability of such provision will have no
effect upon the legality or enforceability of any other provision of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Termination</U>. This Agreement will
automatically terminate on the expiration of the Cooperation Period and shall have no further force and effect, except that Section&nbsp;1(d) and Sections&nbsp;7 through 16 shall survive termination of this Agreement. Notwithstanding the foregoing,
no termination of this Agreement shall relieve any party of liability for any breach of this Agreement arising prior to such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Counterparts</U>. This Agreement may be executed in counterparts and by scanned computer image (such as .pdf), each of which will be
deemed to be an original copy of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>No Third-Party Beneficiaries</U>. This Agreement is solely for the benefit of the
Company and the Elliott Parties and is not enforceable by any other persons. No party to this Agreement may assign its rights or delegate its obligations under this Agreement, whether by operation of law or otherwise, without the prior written
consent of the other parties, and any assignment in contravention hereof will be null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>No Waiver</U>. No failure or delay
by any party in exercising any right or remedy hereunder will operate as a waiver thereof, nor will any single or partial waiver thereof preclude any other or further exercise thereof or the exercise of any other right or remedy hereunder. The
failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Entire Understanding; Amendment</U>. This Agreement and the Information Sharing Agreement, together with the
confirmation delivered by the Elliott Parties&#146; counsel on their behalf simultaneously with the execution hereof, contain the entire understanding of the parties with respect to the subject matter hereof and supersede any and all prior and
contemporaneous agreements, memoranda, arrangements and understandings, both written and oral, between the parties, or any of them, with respect to the subject matter of this Agreement and the Information Sharing Agreement. This Agreement may be
amended only by an agreement in writing executed by the Company and the Elliott Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Interpretation and Construction</U>. The Company and each Elliott Party acknowledges
that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said counsel. Each party and its counsel cooperated and
participated in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties will be deemed the work product of all of the parties and may not be construed
against any party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application
and is hereby expressly waived by the Company and each Elliott Party, and any controversy over interpretations of this Agreement will be decided without regard to events of drafting or preparation. References to specified rules promulgated by the
SEC shall be deemed to refer to such rules in effect as of the date of this Agreement. Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words
&#147;without limitation.&#148; When a reference is made in this Agreement to any Section, such reference shall be to a Section of this Agreement, unless otherwise indicated. The headings contained in this Agreement are for reference purposes only
and shall not affect in any way the meaning or interpretation of this Agreement. The words &#147;hereof,&#148; &#147;herein&#148;, &#147;hereto&#148; and &#147;hereunder&#148; and words of similar import when used in this Agreement shall refer to
this Agreement as a whole and not to any particular provision of this Agreement. The word &#147;will&#148; shall be construed to have the same meaning as the word &#147;shall.&#148; The word &#147;or&#148; is not exclusive. The definitions contained
in this Agreement are applicable to the singular as well as the plural forms of such terms. Any agreement, instrument, law, rule or statute defined or referred to herein means, unless otherwise indicated, such agreement, instrument, law, rule or
statute as from time to time amended, modified or supplemented (and, in the case of any law, rule or statute, includes the other rules and regulations promulgated thereunder). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized signatories of the parties as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>ELLIOTT PARTIES</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Elliott Investment Management L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elliot Greenberg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Elliot Greenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Elliott Associates, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Elliott Investment Management L.P., as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elliot Greenberg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Elliot Greenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Elliott International, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: Elliott Investment Management L.P., as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elliot Greenberg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Elliot Greenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Vice President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B><U>THE COMPANY</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>BioMarin Pharmaceutical Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Alexander Hardy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Alexander Hardy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PRESS RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Filed separately as Exhibit 99.1 to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K.]</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF STRATEGIC AND OPERATING REVIEW COMMITTEE CHARTER </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STRATEGIC AND OPERATING REVIEW COMMITTEE CHARTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Purpose of the Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Strategic and Operating Review Committee (the &#147;Committee&#148;) is being formed as an ad hoc committee of the Board of Directors (the
&#147;Board&#148;) of BioMarin Pharmaceutical Inc. (the &#147;Company&#148;) in order to conduct a review of the Company to maximize its long-term value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of its purpose, the Committee shall review, evaluate and make recommendations to the Board regarding the following matters,
including (to the extent applicable) the timing for, and implementation of, such matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The business, strategy and operations of the Company, including identifying potential operational improvements
and strategic opportunities that may enhance the Company&#146;s long-term value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company&#146;s financial and capital allocation priorities, including relevant operational targets, including
margins; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Long-term planning and priorities, including multi-year financial planning; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any other related matters as may be determined by the Board from time to time. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Membership of the Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment and Removal </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to the Cooperation Agreement, entered into among the Company and Elliott Investment Management L.P.,
Elliott Associates, L.P. and Elliott International, L.P., dated as of December&nbsp;20, 2023 (the &#147;Cooperation Agreement&#148;), each member of the Committee shall be appointed by the Board and shall serve at the discretion of the Board until
such member&#146;s successor is duly appointed (or until such member&#146;s earlier resignation, removal, death or disability). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to the Cooperation Agreement, a member of the Committee shall be automatically removed if the member
(1)&nbsp;is no longer a Director of the Company or (2)&nbsp;is ineligible as a Director because of other rules or requirements. Subject to the Cooperation Agreement, Committee members may otherwise be removed or replaced by vote of the Board.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Number and Qualifications </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Subject to the Cooperation Agreement, the Committee shall be comprised of five directors, including the
Company&#146;s Chief Executive Officer and Chairman of the Board. The initial five members shall be Alexander Hardy, Richard Meier, Maykin Ho, Mark Enyedy and Barbara Bodem. The majority of the members must be &#147;independent&#148; as that term is
defined by Nasdaq and, if applicable, the Sarbanes-Oxley Act. Members must have no material relationship that, in the judgment of the Board, would interfere with his/her exercise of judgment as a Committee member. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Committee Structure and Operations </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Board, taking into account the views of the Chair of the Board and the members of the Committee, shall
designate one member of the Committee as its chair (the &#147;Chair&#148;). The initial Chair shall be Richard A. Meier. Any successor Chair shall be selected by the Board. The Chair is expected to chair all regular sessions of the Committee and be
responsible for setting the agendas for Committee meetings. In the absence of the Chair, the Committee shall select another member to preside. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Committee shall meet when deemed necessary or desirable by a majority of the Committee or by the Chair;
provided that the Committee shall meet at least once per month, unless otherwise approved by its members. The Committee may invite such members of management and other persons to its meetings as it may deem desirable or appropriate. The Committee
may exclude anyone with a personal interest in the matters under discussion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Committee shall maintain written minutes of its meetings and shall cause such minutes to be filed with the
minutes of the meetings of the Board. The minutes of the Committee shall be made available to the other members of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A majority of the members of the Committee shall represent a quorum of the Committee for any decisions for which
authority has been expressly delegated to the Committee by the Board and, if a quorum is present, any action approved by at least a majority of the members of the Committee shall represent valid action of the Committee. Notwithstanding the
foregoing, the Committee does not have decision-making authority except where, and only to the extent that, such authority is expressly delegated by the Board, including as described in this Charter. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Committee Duties and Responsibilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The duties and responsibilities of the Committee are to review, evaluate and make recommendations to the Board regarding the matters described
above under the heading &#147;Purpose of the Committee.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Committee members have the duties and responsibilities set forth
in this Charter, nothing contained in this Charter is intended to create, or should be construed as creating, any responsibility or liability of any individual Committee member, except to the extent provided under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Committee Reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee shall regularly report to the full Board summarizing the Committee&#146;s meetings, including the principal subjects discussed, any significant
issues considered and the conclusions and recommendations of the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of the Committee&#146;s review shall be provided to the Board
prior to August&nbsp;31, 2024, in advance of the Company&#146;s planned 2024 Investor Day. The Committee shall consult with management and the Board with respect to the Company&#146;s communications to be issued in connection with the Investor Day
and the timing thereof, with the goal of having such Investor Day occur at an appropriate time following the Board reaching its determinations regarding the Committee&#146;s review (it being understood that the Board and management have the
discretion to determine the date of the Investor Day and to determine to execute on or announce any initiatives or announce the completion of any initiatives prior to the Investor Day). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Term of the Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee shall continue in existence until the later of (i)&nbsp;the Company&#146;s planned 2024 Investor Day and (ii)&nbsp;the
Company&#146;s quarterly earnings announcement for the third quarter ended September&nbsp;30, 2024, at which time the Committee shall disband, unless otherwise determined by the Board. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Resources and Authority of the Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the Committee&#146;s purpose, the Committee has the authority to retain such advisors as it determines appropriate to assist
in the review, which may include advisors already retained by the Company, in each case at the expense of the Company without seeking approval of the Board or management. The Committee may select an internal or external legal, accounting or other
advisor or consultant only after taking into consideration the independence of such internal or external legal, accounting or other advisor or consultant using factors established by law, the rules and regulations of the SEC and the requirements of
Nasdaq. The Committee is authorized to have full access to all Company personnel, books, records, facilities and other informational sources. Management of the Company shall provide assistance to the Committee in connection with the Committee&#146;s
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee shall not have independent decision-making authority and shall only make recommendations to the Board, and the
results of the Committee&#146;s review and any recommendations of the Committee to the Board shall be confidential, <FONT STYLE="white-space:nowrap">non-binding</FONT> and advisory in nature. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cooperation Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, matters relating to the appointment and removal of directors from the Committee, amendments
to this Charter, and certain other matters, are subject to the terms and provisions of the Cooperation Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adopted:
December&nbsp;20, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d488420dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g488420g1220193204277.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Contacts:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Media</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Traci McCarty</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Marni Kottle</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>BioMarin Pharmaceutical Inc.</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>BioMarin Pharmaceutical Inc.</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>(415) <FONT STYLE="white-space:nowrap">455-7558</FONT></I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>(415) <FONT STYLE="white-space:nowrap">218-7111</FONT></I></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BioMarin Announces Governance Enhancements and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Value Creation Initiatives </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Board Approves Appointment of Three New Independent Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Establishes Strategic and Operating Review Committee of the Board </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>BioMarin Enters into Cooperation and Information Sharing Agreements with Elliott </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN RAFAEL, Calif. &#150; December</B><B></B><B>&nbsp;20, 2023 &#150; PR Newswire &#150;</B> BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global
biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has approved the appointment of three new independent directors: Barbara Bodem, Athena Countouriotis, M.D., and Mark Enyedy effective
December&nbsp;27, 2023. With these appointments, the company&#146;s Board will temporarily expand to 15 directors before returning to 11 directors effective no later than the 2024 annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMarin&#146;s Board has also established a new Strategic and Operating Review<I> </I>Committee to conduct a review of the company to maximize its long-term
value, including a review of the company&#146;s business, strategy and operations, financial and capital allocation priorities, and long-term planning and priorities. The Strategic and Operating Review Committee will be chaired by BioMarin Board
chair Richard A. Meier and will include president and chief executive officer Alexander Hardy, BioMarin director Maykin Ho, Barbara Bodem and Mark Enyedy. The committee will present its recommendations to the full Board. The company has also
committed to holding an investor day in 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of this process and to facilitate collaboration with Elliott Investment Management L.P. (together
with its affiliates, &#147;Elliott&#148;), one of BioMarin&#146;s largest investors, BioMarin has entered into a Cooperation Agreement with Elliott and agreed to customary standstill, voting, and other provisions. Additionally, Elliott has entered
into an information-sharing agreement to allow for a dialogue between Elliott and the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to welcome Barbara, Athena, and Mark
to our Board,&#148; said Mr.&nbsp;Meier. &#147;Their deep industry experience, leadership expertise, and diverse skills will add valuable insight to our Board. The addition of these directors and the new committee will build on the extensive work
our Board has already done to determine how best to strengthen operational performance, enhance profitability, and create long-term value for our shareholders. The Board looks forward to receiving the committee&#146;s recommendations.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I&#146;m looking forward to working with the Board, Elliott, and our newly appointed directors,&#148;
said Mr.&nbsp;Hardy. &#147;Today&#146;s announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders. Our focus will be to grow our business through the commercialization
of our leading portfolio and pipeline of innovative medicines, while driving increased profitability through margin expansion.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elliott Senior
Portfolio Manager Marc Steinberg said, &#147;Our discussions with BioMarin have been positive and productive, and we are pleased to have worked collaboratively to reach this agreement. BioMarin plays a pivotal role in the treatment of genetic
diseases thanks to its globally leading rare-disease portfolio. We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of
BioMarin&#146;s value creation story. We thank the Board and management for their constructive dialogue, and we look forward to continuing our work with them.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC and Goldman Sachs are serving as BioMarin&#146;s financial advisors and Jones Day is serving as BioMarin&#146;s legal counsel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Biographies </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Barbara Bodem</B> has extensive
Board experience, currently serving on a number of boards including Syneos Health, Enovis Corporation, and BiomEdit. Ms.&nbsp;Bodem is also a board member for the Nature Conservancy of Indiana, a nonprofit working to protect ecologically important
lands and waters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Bodem recently served as Interim Chief Financial Officer for Dentsply Sirona Inc., the world&#146;s largest manufacturer of
professional dental products and technologies. This follows her time as Senior Vice President&nbsp;&amp; Chief Financial Officer, and interim CIO, for Hillrom where she was responsible for both financial and information technology and where she
oversaw portfolio transformation and performance acceleration, which led to Hillrom&#146;s successful acquisition by Baxter for $12&nbsp;billion, inclusive of debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this, Ms.&nbsp;Bodem was Senior Vice President of Finance for Mallinckrodt Pharmaceuticals. At Mallinckrodt, Ms.&nbsp;Bodem was responsible for
corporate business development and licensing and reported to the Chief Financial Officer. Before this, she was Vice President of Finance, global commercial operations for Hospira and earlier held several positions of increasing responsibility at Eli
Lilly and Company, culminating in Chief Financial Officer, Lilly Oncology. She began her career as a Financial Analyst for Irwin Management Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, Ms.&nbsp;Bodem served on the boards of Turning Point Therapeutics and Invacare Corporation. Ms.&nbsp;Bodem earned a M.B.A and a B.S. in Finance
both at Indiana University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Athena Countouriotis, M.D.</B>, is co founder, President, Chief Executive Officer and Chairperson of Avenzo Therapeutics.
She most recently led Turning Point Therapeutics as President and Chief Executive Officer through its initial public offering (IPO) to its eventual acquisition by Bristol Myers Squibb for $4.1&nbsp;billion in August 2022. With nearly 20 years of
industry experience, she has served as an officer in both public and private companies, led multiple initial public offerings and acquisitions, and guided several development programs to approval in the U.S. and Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Countouriotis previously served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, and as Senior Vice President and
Chief Medical Officer of Halozyme Therapeutics. She also served as Chief Medical Officer of Ambit Biosciences, where she helped lead the company&#146;s </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IPO and was responsible for the clinical development of Vanflyta<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> until the company&#146;s acquisition by Daiichi Sankyo in November 2014.
Earlier in her career, Dr.&nbsp;Countouriotis led various clinical development organizations within Pfizer and Bristol Myers Squibb for oncology therapeutics including Sutent<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Mylotarg<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, Bosulif<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Sprycel<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Countouriotis also serves on the boards of Iovance Biotherapeutics and Passage Bio. Dr.&nbsp;Countouriotis earned a B.S. from the University of
California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial medical training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research
Center in the Pediatric Hematology/Oncology Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mark Enyedy</B> has served as the President and Chief Executive Officer of ImmunoGen since 2016.
Mr.&nbsp;Enyedy has nearly three decades of combined general management, business development and legal experience in the biotechnology industry. Mr.&nbsp;Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head
of Corporate Development, leading the company&#146;s strategy, M&amp;A, and corporate planning functions and providing commercial oversight for the company&#146;s <FONT STYLE="white-space:nowrap">pre-Phase</FONT> 3 portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, Mr.&nbsp;Enyedy served as Chief Executive Officer and a director of Proteostasis Therapeutics, following 15 years at Genzyme Corporation in
diverse roles, most recently as President of the transplant, oncology, and multiple sclerosis divisions. Before joining Genzyme, Mr.&nbsp;Enyedy was an Associate with the Boston law firm Palmer&nbsp;&amp; Dodge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Enyedy also serves on the boards of The American Cancer Society of Eastern New England and the Biotechnology Innovation Organization. He previously
served on the boards of Ergomed plc, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals. Mr.&nbsp;Enyedy holds a J.D. from Harvard Law School and a B.S. from Northeastern University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About BioMarin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Founded in 1997, BioMarin is a global
biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin&#146;s unparalleled research and development
capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The company&#146;s distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT> or offer a substantial benefit over existing treatment options. For additional information, please visit&nbsp;www.biomarin.com.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, our plans, expectations and long-term goals associated with our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.
These risks and uncertainties include, among others: the results of the review to be conducted by the Strategic and Operating Review Committee; finalizing the appointment of the anticipated new Directors, BioMarin&#146;s success in the
commercialization of its commercial products, impacts of macroeconomic and other external factors on BioMarin&#146;s operations; results and timing of current and planned preclinical studies and clinical trials and the release of data from those
trials; BioMarin&#146;s ability to successfully manufacture its commercial products and product candidates; and those factors detailed in BioMarin&#146;s filings with the Securities and Exchange Commission (SEC), including, without limitation, the
factors contained under the caption &#147;Risk Factors&#148; in BioMarin&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended Sept.&nbsp;30, 2023 as such factors may be updated by any subsequent reports.
Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement,
whether as a result of new information, future events or otherwise. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>bmrn-20231220.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/21/2023 2:42:05 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:bmrn="http://www.bmrn.com/20231220"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.bmrn.com/20231220"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20231220_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20231220_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bmrn-20231220_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/21/2023 2:42:05 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bmrn-20231220_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/21/2023 2:42:05 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="bmrn-20231220.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g488420g1220193204277.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g488420g1220193204277.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P .D# 2(  A$! Q$!_\0
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M"FGZG>&ZE\Q9&QNVMP:VHHE@A2).$10HSZ"N.#J.3YEIT.ZI&BH1<&V^H\D
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MZPZBJFX*C>DK7T8H*;K6JN]M497Q'_Y$>_\ ^ _^A"MK0/\ D7=-_P"O:/\
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M'80RH4D2W164]00HR*O44.H^10\[C4%S\_E8XO7-,O;CXBZ#?16[O:P(XDD
MX7/K7:4443J.22?30(046WW,S7]#M/$.DRV%XN5<?*XZHW8BL?X?Z-=:!H-Q
DIUVN)([M]K=G7"X8>QKJZ*%5DJ;I]!.E%S53J%)2TE9FA__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140358683810080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMARIN PHARMACEUTICAL INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001048477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 20,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0397820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">770 Lindaro Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Rafael<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d488420d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmrn-20231220.xsd" xlink:type="simple"/>
    <context id="duration_2023-12-20_to_2023-12-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-12-20_to_2023-12-20"
      id="Hidden_dei_EntityRegistrantName">BIOMARIN PHARMACEUTICAL INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2023-12-20_to_2023-12-20">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-12-20_to_2023-12-20"
      id="Hidden_dei_EntityCentralIndexKey">0001048477</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-12-20_to_2023-12-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-12-20_to_2023-12-20">2023-12-20</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-12-20_to_2023-12-20">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-12-20_to_2023-12-20">000-26727</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-12-20_to_2023-12-20">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-12-20_to_2023-12-20">770 Lindaro Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-12-20_to_2023-12-20">San Rafael</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-12-20_to_2023-12-20">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-12-20_to_2023-12-20">94901</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-12-20_to_2023-12-20">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-12-20_to_2023-12-20">506-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-12-20_to_2023-12-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-12-20_to_2023-12-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-12-20_to_2023-12-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-12-20_to_2023-12-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-12-20_to_2023-12-20">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-12-20_to_2023-12-20">BMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-12-20_to_2023-12-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-12-20_to_2023-12-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( -V*E%<'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ W8J45]<R6<CM    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ W8J45YE<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #=BI17
M'3U+"TX$  "-$   &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ W8J45Y^@&_"Q @  X@P   T
M     ( !D P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #=BI17EXJ[',
M   3 @  "P              @ %L#P  7W)E;',O+G)E;'-02P$"% ,4
M" #=BI17'#AEZC\!   \ @  #P              @ %5$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ W8J45R0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MW8J45V60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d488420d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bmrn-20231220.xsd</File>
    <File>bmrn-20231220_lab.xml</File>
    <File>bmrn-20231220_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d488420d8k.htm">d488420d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d488420d8k.htm": {
   "nsprefix": "bmrn",
   "nsuri": "http://www.bmrn.com/20231220",
   "dts": {
    "schema": {
     "local": [
      "bmrn-20231220.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "bmrn-20231220_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmrn-20231220_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d488420d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-12-20_to_2023-12-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d488420d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-12-20_to_2023-12-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d488420d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.bmrn.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-300042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-300042-xbrl.zip
M4$L#!!0    ( -V*E%<,71G4- ,  $$+   1    8FUR;BTR,#(S,3(R,"YX
M<V2]5FU/VS 0_H[$?[CETR8M<1/&)"(*8@,D)&!3@6G?D)M<6VN.G=D.T'\_
MVTE*^KH"T_JEKN^>N^=>W</CIX+# RK-I.@'<=0+ $4F<R;&_:#2(=498\'Q
MT>[.X;LPA-/SBVL(86),J5-"'A\?HWS$A):\,M:"CC)9$ C#5O_K[1W\J*VG
M,$".5",45!M4\*5B/$^37K(7]^(D2KHPA=39@YP:3"%.2!(3IPE)^BE)>_MP
M<@5GWHR 6U9@%RO+J6+CB8'WV0?PH%,I!'*.4SAG@HJ,40XW+>6/<"&R"$XX
MAX&#:<M3HWK /&JL/ND\U=D$"[J[ V 3)G0JK,FJZ <N$TTBGH:*1U*-26X4
M,=,2B54*K18JE@4=Z-]Q2QA;"2?1,^"(ZJ$'M1*?G@YB6"@QY\9=^/+XC"=)
MKZ.<(YOI>CH:LV@L'X@5+!IV<K8Z@*37VR.V&XS-,78@G(E?&Q!./+2-T76R
M!'G<\X#XX." >.D"I=S,1]!8WR>UT&M38Q0;5@;/I2I.<40K;E&5^%U1SD8,
M<Z]EN[1 8>9TYC4,56,TU[1 7=(,MTZS;:15,5F:,?EY=7GC>RPX<@  WW:L
M**4R4'??I<S\5&Q(I?L5MA4(W548)^%>'%EC 8B5C->4#\B;B;2%?16165=L
M342OZUYW"-UAG??5/?_J#"P.LHO_P,4??]XJ_J5%\ ^82'']5C*=;?;ZF@C*
MLGI9U<?MZ_*,?%-OMAO!Y6%_H^/%%=)X]3ZI$-)X1UTFM"R9&,GFREZZ)D[;
M3A[@"/SJ2JG*E.2X><&14LD2E6%VN3\/0VU@HG#4#]RN"=L]<\_I,+)[IE59
M<C _7DY,+ 3YY3.]%FN8<>!+)P8GMZ\DY3/3KAWZ@;9YYYWQ_,_AE@I?&JZ%
M:+O9?=G61_V]H_7BX)V?6ZL![G WN%C]-LP>!V+HDQ2RF-8$3V56N;>G_3X1
M^9FPM*87MJM4X2D%P.PK,K#J]UNISPBV%'.T_]B8;]VXYS[V#UUKH7ND(H?:
M''3L'9)%(XOV*XWY-W'DSQGE6<5G"6_ C<8FX&*IMD<^,UN/:V[;8K4C3!9G
MN+GISGI]5>\:^_,/4$L#!!0    ( -V*E%?+3+_K7@8  +]#   5    8FUR
M;BTR,#(S,3(R,%]L86(N>&ULS9QO;]LV$,;?%^AWN'EO-J"R8V=[4:-ID3G)
M$"QM@L;=A@U#(4N,34SF&:2<V-]^I/XT<DS)4GB:\J*I(MT]=X_S.X:6[;S[
ML%E&<,^DXBA.>L/^40^8"##D8G[26RO/5P'G/5"Q+T(_0L%.>ENF>A_>OW[U
M[CO/@[.+RT_@P2*.5VH\&#P\//3#.RX41NM82ZI^@,L!>%X>/YE^@=_3<F/X
MS"+F*P9+7\5,PB]K'H7CT='H>'@T'/5'Q33)?*,'H1^S,0Q'@]%P8")A-/YI
M-#[Z&4X_PGDB(V#*EZR8BZNMY/-%##\$/T*2=(9"L"AB6[C@PA<!]R.XS5M^
M Y<BZ,-I%,%GDZ9TGXK)>Q;V,]6(BW_'YLO,= ^O7P'HAU&HY-Q)SSP8V6.Q
MF<FHCW*N>STZ'N0IO<>,S5[*PW&2,'S[]NT@N5J,5MP6J\6'@S\_7MT&"[;T
M/?WPZQ]7D)51?*R2\U<8)(]AC0:A-,)\Y^5AGCGE#4?>\;"_46'OO2F8/3K^
MC$57^@@2#V.)$:LH;"XGU7M9?+Q=Z7BVB9D(6:;\31N#+&HAV5VJ:N!+)!4+
M^G.\'X2,)X"8 \\<F Z_U]]\G:#F_72F8ND'\6Z]R#Q$*/.3B8F3GB5IL-N0
MB3N5P8Z6+X-<1Q\>\)]%# +4/[=5["6*>?J=Q*6UBZP<6BY^C6:1M4U#DCXR
MX\V$]^7VD-=4J&A,,H5KJ?%J\J--_+Q/E.'O7/N?=X/'VB^E5;V$*';5M%\W
M),]%S./M9S;GII"(/_E+5I=,>VY'@%8:P?(8%US+]8BH30O 8P4P)9S9;:_O
M(L)-FW<#^72IUVO]+[Z(_'E=@I\D=82NO76T7'2!U2)$1.DW93#2SG2VT&@1
MR[K=4JRK$UU&^M&EWDEL?F/;9@OK7G*G*VN9%:P(<E];K8*TBVM6 I(:H(L0
M+:^MM&Y97QOT[X;T&09K,S=3W7U=DG=S.@+8VCCN7W/!=5^'B-)<&(RR,YKT
M;1:)K-DK#88W3'(,ST5XII^8-^7Q27+'8-JM8$40!:H606IFTQ*@:X I0H9O
M"ZU;.:[=/\5FX5($*%<HDULEM[&N-\&U7MNW$PP;/B<[(-7I1J*>3:R=XK[)
MJ"%/N^78*0A)1<A*@JE)M /Y'WQ9]B//-T<Q1!<\8I_6RQF3S2:FF-?I>%@,
MH/VZ._A/M6@I-^J0RA,!3=VOA=Y:35. .O4WEZ'^'</O>'IS_#G4EHITBO A
M:U@CV!WN2F%:TG4IV*U%RWVK5BQ#\ P_%"-Q&H;:@,K^N^*"#9N-@U6@TU&H
MLH0' MU'H%24%O],_TU^ *827 NJ?4QK-BSH/\,+(?H3?7@MI_@@G@5^,?TE
M8&^Q8X/^,8P,^:>2+0%OR@!*,(5H8:<V4(5Z/1>$F"=/"J[EC<1[+H*&SVW+
M-%X"\&7&;-0_B25#WZK;$O_ILSN-3EZ-=@A:L5(U"0W\$([##:K8C_[BJ^8W
M>NP*+V$4[*9L@[ 3238&%M66AB"M!+H4Y<V;]FQ4#4!M+XYOA#(&)?.; +^;
MT]7;H&R-X_XUIS=![>D0@9O\GC?*-)S2][GS!JB:S;J!:-Z9&-TL4#2\:;B?
MUQ&0I0;0?MT%3+L6$9R)."3J5#=/VNFW"&F3IMU _4/R.&9B@LOE6F0W951=
M6DN2.T*VV@I6!+G 6R%(1'!6 79+.%/<8N-%E)MV[X;S+48\X#$7\X]ZQRVY
M']5EV9;9$<@5)K LP@7A,C4B?A_E(==WAK>MEHOD-NK;#=L;R<Q\,(U%\BX:
M\Q$!>7UW5W_C4*70$<8U3.&A2!>L#ZD2X:W+0+$.I(4@J>0,>MLFBL _TPDI
M^I=*K9ET'P"+SLL8@W*#]F'8BR<<B1+MM@8C+=?J?+3DJ')*&MERW-ZP8*WW
M4]OA:#;E<53['L=^7E=;FS(#:+_NM*VQ:E%M:C)QT.J0R+OO:5KI=V='TZ!I
M-U"GTC<?N+W=+F=8>PO^)*DC1.VMH^6B"YP6(2(R,V5(I9VI;*'1(I)UNZ59
M-\\WP4*[94T^C6C/[7C]M!K!\AB*=71?CWHMS2O0?!JQO;ZM:VK-YBE>WSM?
M,CG74_.KQ(=XH3<C*U\T_!!8B42GK_!5V\*#H>ZO\57($K&>O3"6%X*T$F2E
MB%[C:]&&Y46^NEZ*)Z[TD?F[$]DIGO[U!7WF/U!+ P04    " #=BI170?#=
M [$$  !U*@  %0   &)M<FXM,C R,S$R,C!?<')E+GAM;-6:78_B-A2&[U?:
M_^"F-ZW4$!)FV@X:=D69F0IUO@1L6_5F99(#6'7LR#8#_/O:!E<$PI1,MU7,
M!1^.W^/7YW$<Q^3ZXSJGZ 6$))SU@KC5#A"PE&>$S7O!4H98IH0$2"K,,DPY
M@UZP 1E\_/#^W?5788AN[H:/*$0+I0K9C:+5:M7*9H1)3I=*AY2ME.<1"D-7
M?S#YA'[=-M=%(Z" ): <2P4"_;0D-.LF[:03M^.DE>S+!& 3#V5801?%293$
MD:F)DNY%TFU?HOX#NK5A&)J0'/:UO-@(,E\H]$WZ+;*B&\X84 H;=$<89BG!
M%(V=Y>_0D*4MU*<4C8Q,:I\2Q MDK5U42MB?7?,V->[1^W=(OW0BF;2EO<"D
M8Y>-]530%A=S[;;=B9PHV->LCT2KCI7$5U=7D3U:KB])56W=0!S]_G _3A>0
MXU!#T-#2@Z:TFTS]K=XW=QEM#[KZDG2EC73/4YO[,[J%3M8POT)7+31%89R$
MG;BUEEGPP32YS:K@%$8P0^;STVA8:G.:"V;'DR4?)TD[4GC-&<\WD:D?W?!T
MF0-3[K//LENFB-H,V8R+W/8B0#:AW86 62\P(4,7S7CY>J0#?:X32&T*?5)(
MDA<4 A3M]:40>MPP96O?ZX*2 -8*6 :9"V,Z\!_T]L.6YF[(\K34>W?66E02
MTM:<OT09$-NB^6)38].B?WP><#U1]*=2"9RJ<O>I&2-<N$**IT![084H^I*&
MMMT=P9R8\$P]XAS.]56M+=O;!]@7:2DR%JF+JK\>T2N/_EV-J,!"QPO3A9[H
MG'HF>%Z9JEUK_#6_7&0@>D&2M/3)'Z!"$"YT-5T2H*74EGAAS&-JCL$,A(#L
M?IN$DV:M4SV12K UOS"SOAZJF1FN=Q3/SX5U(&HNI0.C#D_'&SS;83;0/1"8
M#O4$M?X%-O7.J2-Q<W&=,.RP77B#S5T#)CJ-Y](J:YH+J>S3L?G>.S;/H+WJ
M2W1VH]>P=2$=B)M/Z\"PP_:#-]C<6BKEHN#"YG:L4PP#OM33Q6; LYIKC7\(
MU5RD9]EW@'_T#/ =H?"XS*<@ZM'<US4=W;Y7Q^G*,TX3O!YF.@UD1K:WHV^!
M=C)(TPF>-+[#V6E[AK.?93K)<O>A[XXAKH>R,D#3,5::=@AC/Q$.]-<G,>$K
M]B: ^W)/\.U;=O#\N0$O=<5>QY_$L^ OQ.P5OH7@40Q/,![Y=BQ]NUO?]>>9
M2X7I'Z2HOS2MCN )QP/7CJ(_-^]F/ND+P'6XE37-)57VZ=A<>L/&_/E!GQ><
MU;Q).-8UE]&Q5\?)GTV6W[0_!6S \WS)=FMD>2ZL$^+F$CMAV&'S9Y-ES"E)
MB2)L_J OQH(8:^<QJU(V%UB56T?+GQV39P%FR(%>+=D-6?,'IGB:S<Z?%E^+
MT%QZK[EV%/W93SGHS5#*)8A_S[(BCC=$*[SON%[XL[$RAG1I+,;)=$(4/7LI
M>:QK+K=CKXZ3/[LG$X'-XU7C33[E9U_N#D3-)71@U.'Q9W_$#;';=;K ; YU
M'BJIUC875K5?Q\RW?9#;',1<C[V?!5^IA9[?"\QJ/KMP(D1S";YJVX'\'[9"
MKJ.CU-SK O.TY/:(>3//_NF2OP!02P,$%     @ W8J45]M=\N$0(   $JD
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M34Z/PZ;70K?Q:YOQ$[<9[_RESU7)"=K'H^^KQ9<5NWN=N99XHC.YK^(:=7=
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MS3Q'HE?R?%\S+^LK=WL4OU"ON^UHOFM<]:X^4/X,?H&0.SC\?U!+ P04
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M\()W.W)NC6?0'8,T!@;<ED<W7\B.7<@WX$8CYD:Y7?HD\&B?^=$*2@B1.5R
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MSE#OD/SVFJ_=!&DLQH^%7QP5^;DB@8.>SYK@F7F7G \6!=97M1\U<74L)&A
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M?>/;*76J4L1(?#N;$[#,.S"8KTYVFO0U%I?JF*'N(MIJC[>R@&=-,X; [\6
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M!7R.V!K;MJ$6<'03@%\AV[>=NCPUO)U(O:FO@XBB=+D*D;OI^/-J@566D.Z
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M3!,^AIW+=D9T>V^\J<8+A7.4ILG^T5F ;''[2&!8> PW>$6GNT@&#1URH]7
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M'7'K-#T/O)[GI$QT-SUGW4R %GFZO(^9='J[8(U*6Q5:)F0UHM1C5U(0)=^
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MFP/$?;3_.WSXYNS=VQ?_"U!+ P04    " #=BI17?R1#"-X4  !W0@  $0
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M6(7KD$,WW!6+*A=3\,8L-00^,:L##ADP,LEL$_:-A<6&U-Q$H<K$'<> P,>
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M=?HED*G.Z7,4F< %Q12(R^"2RG;6_"V-8"^6 I?KV[J"?.&K,P6C:P+1YQ)
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MMW,10ULA)=UI2V;OBGX8:GH#_ J *]=M2--N.7'(PA4AV;2>D,A*+KH'OKF
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MF,PBESL<2SY>\?N1'_3A#9<-?M.%ES:*BW;KL7[!,)N9F$: % G.J >,]=?
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M_Q]._"]02P$"% ,4    " #=BI17#%T9U#0#  !!"P  $0
M@ $     8FUR;BTR,#(S,3(R,"YX<V102P$"% ,4    " #=BI17RTR_ZUX&
M  "_0P  %0              @ %C P  8FUR;BTR,#(S,3(R,%]L86(N>&UL
M4$L! A0#%     @ W8J45T'PW0.Q!   =2H  !4              ( !] D
M &)M<FXM,C R,S$R,C!?<')E+GAM;%!+ 0(4 Q0    ( -V*E%?;7?+A$"
M !*I   .              "  =@.  !D-#@X-#(P9#AK+FAT;5!+ 0(4 Q0
M   ( -V*E%?$(\8"(DX  +*3 0 1              "  10O  !D-#@X-#(P
M9&5X,3 Q+FAT;5!+ 0(4 Q0    ( -V*E%=_)$,(WA0  '="   1
M      "  65]  !D-#@X-#(P9&5X.3DQ+FAT;5!+!08     !@ & '\!  !R
%D@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
